Trials / Completed
CompletedNCT00254137
Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.
A Randomized Phase II-study to Evaluate the Safety and Efficacy of Capecitabine Plus Irinotecan Plus Cetuximab Compared to Capecitabine Plus Oxaliplatin Plus Cetuximab in First-line Treatment of Patients With Metastatic Colorectal Cancer.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (planned)
- Sponsor
- Ludwig-Maximilians - University of Munich · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A randomized phase II-study to evaluate the safety and efficacy of capecitabine plus irinotecan plus cetuximab compared to capecitabine plus oxaliplatin plus cetuximab in first-line treatment of patients with metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | capecitabine | |
| DRUG | irinotecan | |
| DRUG | oxaliplatin | |
| DRUG | cetuximab |
Timeline
- Start date
- 2004-09-01
- Completion
- 2006-11-01
- First posted
- 2005-11-15
- Last updated
- 2010-10-28
Source: ClinicalTrials.gov record NCT00254137. Inclusion in this directory is not an endorsement.